Skip to content
Open access

Identification of Metabolic Phenotypes in Polycystic Ovary Syndrome Using Unsupervised Clustering: A Case-Control Study

Jul 2026 · Pakistan BioMedical Journal · pp. 09-15 · 0 citations · 16 references

TL;DR

Clustering identifies distinct metabolic subtypes, supporting phenotype-based management and exploring the serum androgen-hirsutism correlation finds Serum androgens do not explain hirsutism.

Abstract

PCOS is an endocrine disorder of women. It remains unclear whether adding biomarkers to clinical assessment improves diagnosis, or if androgens explain clinical hirsutism severity. Objectives: To identify metabolic phenotypes via clustering; test if a biomarker panel predicts PCOS better than clinical assessment; and explore the serum androgen-hirsutism correlation. Methods: This retrospective case-control study analyzed Kaggle data (208 PCOS cases and controls). Clinical, biochemical (total/free testosterone, DHEAS, LH/FSH, HOMA-IR, SHBG), and ultrasound (ovarian volume, follicle count) variables were recorded. Logistic regression (clinical vs. full panel) was compared using AUC, DeLong's test, LRT, bootstrap correction, and Hosmer-Lemeshow. K-means clustering (k=2) applied to standardized BMI, HOMA-IR, and SHBG. Pearson correlation assessed FG score. Results: The full model (test AUC 0.596) did not outperform the clinical model (AUC 0.592; DeLong p=0.886; LRT p=0.835). Optimism correction reduced the full AUC to 0.507 versus 0.526 for clinical, with poor calibration (p=0.005). No biomarker independently predicted PCOS. No serum hormone correlated with FG score (|r|≤0.111). Clustering revealed obese/low-SHBG (n=98) and lean/insulin-resistant (n=110) phenotypes, differing in BMI, SHBG, and HOMA-IR (p<0.050), but not testosterone or LH/FSH. Conclusions: Adding biomarkers does not improve diagnosis and is overfitted. Serum androgens do not explain hirsutism. Clustering identifies distinct metabolic subtypes, supporting phenotype-based management.

Read PDF

Similar papers

Review Open access Sep 2026

Serum biomarkers for the diagnosis and management of adolescent polyendocrine metabolic ovarian syndrome: a systematic review and meta-analysis

Summary Background Adolescent polyendocrine metabolic ovarian syndrome (PMOS) poses immediate and lifelong risks to women’s health. However, reliable biomarkers for adolescent PMOS remain elusive in current clinical practice. Methods We systematically searched six databases from inception to April 2026, following PRISM...

Yue Shi, Chi-Chiu Wang, E. Stener-Victorin et al. · 0 citations
Review Open access 2026

Metabolic heterogeneity of polycystic ovary syndrome: from pathophysiology to phenotypic stratification

Introduction. Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders in women of reproductive age; however, its clinical heterogeneity complicates timely stratification of long-term cardiometabolic risk. The lack of a generally accepted algorithm for a differentiated approach at the initial d...

M. Kovarenko, L. Ruyatkina, Yulia G. Samoylova · 0 citations
Open access Sep 2026

Phenotype-Specific Differences in Insulin Resistance and Androgenic Profiles in Polycystic Ovary Syndrome: A Prospective Observational Study

Background and Objectives: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine and metabolic disorder characterized by distinct phenotypic presentations. This study aimed to compare androgenic and metabolic characteristics across Rotterdam-defined PCOS phenotypes, with particular emphasis on insulin resistanc...

Karolin Ohanoglu Cetinel, Ahmet Cinar, Can Tercan et al. · 0 citations
Open access Sep 2026

Association of prolactin with cardiometabolic risk markers in women with polycystic ovary syndrome: a phenotype-based analysis

Compared with controls, women with PCOS had higher body weight, body-mass index, waist circumference, waist circumference, triglyceride levels, insulin resistance-related parameters, triglyceride-glucose (TyG) Index, lipid accumulation product (LAP), and Atherogenic Index of Plasma (AIP), whereas high-density lipoprote...

Hatice Çalışkan Burgucu, Emel Yılmaz Kaya, Ayşen Yümlü et al. · 0 citations
Open access Sep 2026

The Relevance of Follicle Number and Androgens in Metabolic Alterations in Polycystic Ovary Syndrome: A Cross-Sectional Study

Background/Objectives: Polycystic Ovary Syndrome (PCOS) is characterized by reproductive and metabolic disturbances, including insulin resistance and altered ovarian morphology. The clinical manifestations of PCOS include metabolic, reproductive, and psychological issues that negatively affect quality of life, making P...

N. Cera, Joana Pinto, M. Maccarone et al. · 0 citations
Open access Aug 2026

Body mass index outperforms the Rotterdam criteria in defining phenotypic heterogeneity in polycystic ovary syndrome: a multicenter study from the Italian PCOS registry (PCOSOUTCOME.net)

Polycystic ovary syndrome (PCOS) is a common and highly heterogeneous endocrine–metabolic disorder. The Rotterdam criteria identify four diagnostic phenotypes; however, it remains unclear whether these phenotypes or body mass index (BMI) better predict metabolic risk. The PCOSOUTCOME.net registry collects data from mul...

A. Gambineri, S. Federici, E. Maseroli et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.